Safety and efficacy of NOAC vs. VKA in patients treated by PCI: a retrospective study of the FRANCE PCI registry
IntroductionDual antithrombotic therapy (DAT) combining oral anticoagulation (OAC), preferentially Non-vitamin K antagonist OAC (NOAC) and single antiplatelet therapy (SAPT) for a period of 6–12 months is recommended after percutaneous coronary intervention (PCI) in patients with an indication for O...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2024-01-01
|
| Schriftenreihe: | Frontiers in Cardiovascular Medicine |
| Schlagworte: | |
| Online-Zugang: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1320001/full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
